p-EGFR Antibody (15A2): sc-81488

p-EGFR Antibody (15A2) is a mouse monoclonal IgG1 antibody that detects phosphorylated Epidermal Growth Factor Receptor (p-EGFR), of mouse, rat, human, and canine origin by western blotting (WB) and immunoprecipitation (IP). p-EGFR monoclonal antibody (15A2) is available as the non-conjugated anti-p-EGFR antibody form. The Epidermal Growth Factor Receptor (EGFR) plays a crucial role in regulating cell growth, survival, and differentiation through interactions with epidermal growth factors. Upon binding of ligands such as EGF or TGFα, EGFR undergoes a conformational change that activates intrinsic tyrosine kinase activity, leading to autophosphorylation at key tyrosine residues, including Tyr 1068, Tyr 1092, and Tyr 1173. These phosphorylation sites serve as docking platforms for signaling proteins containing SH2 or PTB domains, ensuring precise recruitment and activation of downstream effectors. Autophosphorylation also induces structural changes in EGFR′s intracellular domain, enhancing interaction with multiple signaling proteins simultaneously, amplifying signal transduction. These phosphorylation events are essential for recruiting downstream signaling proteins, such as GRB2, which facilitate activation of the Ras signaling pathway, a critical pathway for cell proliferation and survival. p-EGFR′s ability to mediate these signaling cascades underscores importance in various physiological processes and potential role in cancer progression, making p-EGFR a valuable target for therapeutic intervention and research. anti-p-EGFR antibody (15A2) provides researchers with a reliable tool to study EGFR phosphorylation and role in key signaling pathways, advancing understanding of function in normal physiology and oncogenesis.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

p-EGFR Antibody (15A2) References:

1. Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer.  |  Cunningham, MP., et al. 2005. Int J Oncol. 27: 317-25. PMID: 16010411
2. Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas.  |  Magkou, C., et al. 2008. Breast Cancer Res. 10: R49. PMID: 18522728
3. EGFR nuclear import in gallbladder carcinoma: nuclear phosphorylated EGFR upregulates iNOS expression and confers independent prognostic impact.  |  Li, CF., et al. 2012. Ann Surg Oncol. 19: 443-54. PMID: 21761100
4. Combinations of laminin 5 with PTEN, p-EGFR and p-Akt define a group of distinct molecular subsets indicative of poor prognosis in patients with non-small cell lung cancer.  |  An, SJ., et al. 2012. Exp Ther Med. 4: 226-230. PMID: 23139712
5. Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retropective study.  |  Di Lorenzo, G., et al. 2013. J Transl Med. 11: 161. PMID: 23819610
6. IFIT1 and IFIT3 promote oral squamous cell carcinoma metastasis and contribute to the anti-tumor effect of gefitinib via enhancing p-EGFR recycling.  |  Pidugu, VK., et al. 2019. Oncogene. 38: 3232-3247. PMID: 30626937
7. Phosphorylated EGFR (pEGFR T693) as a Novel Predictor of Recurrence in Non-Functioning Pituitary Adenomas.  |  Rai, A., et al. 2021. Front Endocrinol (Lausanne). 12: 708111. PMID: 34295309
8. Estrogen alleviates post-traumatic osteoarthritis progression and decreases p-EGFR levels in female mouse cartilage.  |  Lu, Z., et al. 2022. BMC Musculoskelet Disord. 23: 685. PMID: 35854298
9. In Situ Hybridization (ISH) Combined with Immunohistochemistry (IHC) for Co-detection of EGFR RNA and Phosphorylated EGFR Protein in Lung Cancer Tissue.  |  Oliver, A., et al. 2023. Methods Mol Biol. 2593: 221-232. PMID: 36513934

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-p-EGFR Antibody (15A2) has 13 citations in a variety of scientific publications.

Primary antibodies like Anti-p-EGFR Antibody (15A2) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

p-EGFR Antibody (15A2) Specifications

Alternate Product Name: EGFR

Product Clone Name: 15A2

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁

Amino Acids: Tyr 1068

Epitope Target: EGFR

Epitope Species: human

Product Reactivity/Detection: Tyr 1068 phosphorylated EGFR

Species Reactivity/Detection: mouse, rat, human, canine

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP

Vialing Information: Each vial contains 50 µg IgG₁ in 0.5 ml of PBS with < 0.1% sodium azide, 0.1% gelatin, PEG and sucrose

Research Citations: 13 citations in various scientific publications

Available Conjugates/Forms for p-EGFR Antibody (15A2): N/A

The preferred EGFR antibody is EGFR Antibody (528): sc-120.